Developer docs
API playgroundTry for free, no card

Search company profiles

Grand Life Sciences

Full company profile

uuid002k145

Namestring
Grand Life Sciences
Legal namestring
远大医学营养科学(武汉)有限公司
Websiteurl
dazy.cn
Company typeenum
Private
Founded yearint
2003
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersWuhan, China
HQ citystring
Wuhan
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
injectable pharmaceuticals, lipid microsphere drug delivery, perioperative analgesic injection, active pharmaceutical ingredients, GMP-certified pharmaceutical manufacturing
Industry2 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Injectable Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Manufacturing and Sales
TypeOne Time License
Description

Core revenue stream from development, manufacturing, and sales of pharmaceutical products including injectable drugs (安瓿注射剂, 大输液), active pharmaceutical ingredients (原料药), and oral preparations (口服乳剂). Products are sold through channel partners and direct sales teams to hospitals and medical institutions across China. Revenue supported by national volume-based procurement (集中带量采购/VBP) contracts and commercial market sales.

dazy.cn
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1National Volume-Based Procurement (集中带量采购) - 安抚® Flurbiprofen Axetil Injection
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

安抚® entered national medical insurance procurement, significantly reducing prices compared to imported Japanese product (reduced ~70%). Included in first batch of 25 national VBP products. Estimated annual sales revenue ~400 million RMB (2021 projection).

dazy.cn
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1安抚®
Description

氟比洛芬酯注射液,用于术后及癌症病人的靶向镇痛药物,是公司历经十余年研发的首仿产品

dazy.cn
+1 more record
Core offering1 text field

Grand Life Sciences is a high-tech pharmaceutical manufacturer that integrates drug R&D, production, and sales of injectable medications, active pharmaceutical ingredients, and oral preparations. Its core commercial products are Flurbiprofen Axetil Injection (Anfu®), a lipid microsphere-based targeted analgesic for post-operative and cancer pain, and Simethicone Emulsion (Anboshi®) for gastrointestinal applications. The company operates an 80,000 sqm GMP-certified manufacturing complex in Wuhan covering large-volume infusions, small-volume injections, freeze-drying, and API production, and distributes products to Chinese hospitals through national VBP procurement and provincial distribution partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Flurbiprofen Axetil Injection reduced imported drug price by ~70% upon market entry, saving over 1 billion RMB annually for national medical insurance
+2 more records
Product overview1 text field

Grand Life Sciences (远大医学营养科学(武汉)有限公司) is a high-tech pharmaceutical company integrating R&D, manufacturing, and sales. The company operates as a subsidiary of China Yuanda Group, specializing in medical nutrition and advanced injectable formulations. Its core products include 氟比洛芬酯注射液(安抚®)for pain management and 西甲硅油乳剂(安博士®)for gastrointestinal applications. The company has developed proprietary technology platforms including lipid microsphere carrier drug injection technology and high-activity polysaccharide drug development. Manufacturing capabilities include freeze-dried injection lines, large volume infusion production, quality control laboratories, and API production under GMP certification. The product portfolio is supported by an academician expert workstation and a 30+ person R&D team.

Product and service3 records
1Flurbiprofen Axetil Injection (Anfu® 安扶®)
CategoryInjectable Analgesic Pharmaceutical
Description

A lipid microsphere-based targeted analgesic injection used by hospitals for post-operative and cancer pain management. It is the first domestically manufactured nano-injection product approved in China and the first generic to break Japanese technology monopoly. Contains flurbiprofen axetil as active pharmaceutical ingredient.

2Simethicone Emulsion (Anboshi® 安博士®)
CategoryGastrointestinal Pharmaceutical
Description

A simethicone-based emulsion injection product used for gastrointestinal applications as an auxiliary medication for gastrointestinal examination preparation. Launched in 2022 for diagnostic and therapeutic purposes.

3Alanylglutamine API (丙氨酰谷氨酰胺原料药)
CategoryActive Pharmaceutical Ingredient
Description

Active pharmaceutical ingredient for alanylglutamine injection, produced under GMP certification. The company manufactures both the API and finished dosage forms. Supplied to domestic and international pharmaceutical manufacturers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1辽宁远大诺康生物制药有限公司 (Liaoning Grand Nucam Biopharmaceutical Co., Ltd.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

In January 2020, the company underwent merger and restructuring, joining China Grand Group's pharmaceutical health segment through integration with Liaoning Grand Nucam. This provided access to Grand Group's broader resources, sales networks, and R&D capabilities. The company became part of Grand Nucam's 'Greater Wuhan' pharmaceutical platform. In August 2021, the company name officially changed from 武汉大安制药有限公司 to 远大生命科学(武汉)有限公司.

dazy.cn
2华润湖北医药有限公司 (China Resources Hubei Pharmaceutical Co., Ltd.)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Key strategic distribution partner for安抚® (Flurbiprofen Axetil Injection) in Hubei province. One of China's largest state-owned pharmaceutical distribution companies.

dazy.cn
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Strategic commercial partner for安抚® product marketing and distribution, present at national launch events and regional promotions.

4北京盛世康源医药 (Beijing Shengshi Kangyuan Pharmaceutical)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Strategic commercial partner for安抚® product in the Beijing region market.

dazy.cn
5广东康美药业 (Guangdong Kangmei Pharmaceutical)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Key distribution partner for安抚® product in the Guangdong province market.

dazy.cn
6云南泰康医药 (Yunnan Taikang Pharmaceutical)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Strategic partner in Yunnan province for pharmaceutical product distribution, actively supported regional marketing meetings.

dazy.cn
7合肥亿帆 (Hefei Yifan)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Regional commercial partner for安抚® product distribution in Anhui province, participated in national launch event.

dazy.cn
8南京星鲨 (Nanjing Xingsha)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Regional commercial partner for安抚® distribution in Jiangsu province.

dazy.cn
9河南金保康 (Henan Jinbaokang)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Regional commercial partner for安抚® distribution in Henan province.

dazy.cn
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

The company is designated as a teaching base for HUST Tongji Medical College's School of Pharmacy, facilitating joint talent cultivation and academic exchange programs.

11武汉理工大学 (Wuhan University of Technology)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Designated as a teaching base for collaborative education programs in pharmaceutical sciences and related fields.

dazy.cn
12武汉轻工大学 (Wuhan Polytechnic University)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Designated as a teaching base for collaborative education programs in pharmaceutical sciences.

dazy.cn
13华中科技大学 (Huazhong University of Science and Technology)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-01-01
Description

Long-standing strategic R&D partnership with Huazhong University of Technology (HUST). Professor Chen Bangyin (陈邦银), a State Council special allowance recipient, serves as a special expert. HUST faculty collaborate on research projects including the enterprise academician expert workstation. The company is a HUST Tongji School of Pharmacy teaching base.

dazy.cn
14武汉大学 (Wuhan University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-01-01
Description

Strategic collaboration with Wuhan University. Professor Shu Jiayou (束家有), a State Council special allowance recipient, serves as a special expert and consultant. Dr. Huang Ling was appointed as a graduate student supervisor (校外兼职导师) by Wuhan University School of Pharmacy.

dazy.cn
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Mochida Pharmaceutical
TypeBroad incumbent
Description

Original Japanese developer of Flurbiprofen Axetil (Ropion®) whose technology monopoly Grand Life Sciences' Anfu® broke. Comparable as the originator of the same molecule and a broader specialty injectable manufacturer.

TypeDirect peer
Description

Hong Kong-listed Chinese pharmaceutical major that produces Flurbiprofen Axetil Injection and other injectable analgesic products, directly competing with Anfu® in the same hospital and VBP channels. Comparable in scale and product category.

3Livzon Pharmaceutical Group
TypeBroad incumbent
Description

Hong Kong-listed Chinese pharmaceutical company with injectable, API, and specialty drug products. Comparable in scale and GMP-certified manufacturing for Chinese hospital markets.

4Jiangsu Hengrui Medicine
TypeBroad incumbent
Description

China's largest innovative pharmaceutical company with broad specialty injectable portfolio, including perioperative and oncology supportive care products. Comparable in targeting the same hospital channels and VBP procurement.

TypeDirect peer
Description

Chinese pharmaceutical company with established injectable product portfolios including analgesics and specialty injectables. Both target hospital channels and participate in China's national VBP, making them a direct competitor in the domestic injectable space.

TypeEmerging player
Description

Chinese specialty pharmaceutical company focused on CNS and injectable products, with similar hospital-channel and VBP procurement participation. Comparable in operating scale and specialty injectable focus.

7China Resources Pharmaceutical (Huarun)
TypeOthers
Description

State-owned pharmaceutical distribution and manufacturing conglomerate that operates China Resources Hubei Pharmaceutical, a key Grand Life Sciences distribution partner. Relevant as both a channel partner and ecosystem participant in China's pharmaceutical supply chain.

TypeDirect peer
Description

Distribution partner of Grand Life Sciences for Anfu® in Anhui province. Listed as a regional pharmaceutical and distribution player that intersects with the company's commercial channel and product portfolio.

TypeBroad incumbent
Description

Major domestic Chinese pharmaceutical company with a broad specialty injectable and analgesic portfolio. Competes in the same hospital channels and VBP procurement framework.

10Sino Biopharmaceutical
TypeBroad incumbent
Description

Major Hong Kong-listed Chinese pharmaceutical company with a wide portfolio of injectable and specialty drugs. Competes in similar VBP channels and hospital formularies with comparable product breadth.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Grand Life Sciences

Injectable Pharmaceuticalsdazy.cn

Grand Life Sciences firmographics

Firmographics
Name
Grand Life Sciences
Legal name
远大医学营养科学(武汉)有限公司
Website
https://dazy.cn
Company type
Private
Founded year
2003
Operating status
Operating
Ownership category
akta.pro rank

Grand Life Sciences industry classification

Industry
Product category
Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Injectable pharmaceuticals
  • Lipid microsphere drug delivery
  • Perioperative analgesic injection
  • Active pharmaceutical ingredients
  • GMP-certified pharmaceutical manufacturing

Where Grand Life Sciences is headquartered

Location

Headquarters

HQ city
Wuhan
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Grand Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Pharmaceutical Product Manufacturing and Sales: Core revenue stream from development, manufacturing, and sales of pharmaceutical products including injectable drugs (安瓿注射剂, 大输液), active pharmaceutical ingredients (原料药), and oral preparations (口服乳剂). Products are sold through channel partners and direct sales teams to hospitals and medical institutions across China. Revenue supported by national volume-based procurement (集中带量采购/VBP) contracts and commercial market sales.

Pricing tiers

ModelBillingPrice
Transaction based/ take rateMulti-year contractNational Volume-Based Procurement (集中带量采购) - 安抚® Flurbiprofen Axetil Injection

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Grand Life Sciences product offering

Product offering

Core offering

Grand Life Sciences is a high-tech pharmaceutical manufacturer that integrates drug R&D, production, and sales of injectable medications, active pharmaceutical ingredients, and oral preparations. Its core commercial products are Flurbiprofen Axetil Injection (Anfu®), a lipid microsphere-based targeted analgesic for post-operative and cancer pain, and Simethicone Emulsion (Anboshi®) for gastrointestinal applications. The company operates an 80,000 sqm GMP-certified manufacturing complex in Wuhan covering large-volume infusions, small-volume injections, freeze-drying, and API production, and distributes products to Chinese hospitals through national VBP procurement and provincial distribution partners.

Product overview

Grand Life Sciences (远大医学营养科学(武汉)有限公司) is a high-tech pharmaceutical company integrating R&D, manufacturing, and sales. The company operates as a subsidiary of China Yuanda Group, specializing in medical nutrition and advanced injectable formulations. Its core products include 氟比洛芬酯注射液(安抚®)for pain management and 西甲硅油乳剂(安博士®)for gastrointestinal applications. The company has developed proprietary technology platforms including lipid microsphere carrier drug injection technology and high-activity polysaccharide drug development. Manufacturing capabilities include freeze-dried injection lines, large volume infusion production, quality control laboratories, and API production under GMP certification. The product portfolio is supported by an academician expert workstation and a 30+ person R&D team.

Differentiator

Problem solved

Functional benefit

Brands

  • 安抚®: 氟比洛芬酯注射液,用于术后及癌症病人的靶向镇痛药物,是公司历经十余年研发的首仿产品
  • 安博士®

Products and services

  • Flurbiprofen Axetil Injection (Anfu® 安扶®) A lipid microsphere-based targeted analgesic injection used by hospitals for post-operative and cancer pain management. It is the first domestically manufactured nano-injection product approved in China and the first generic to break Japanese technology monopoly. Contains flurbiprofen axetil as active pharmaceutical ingredient.
  • Simethicone Emulsion (Anboshi® 安博士®) A simethicone-based emulsion injection product used for gastrointestinal applications as an auxiliary medication for gastrointestinal examination preparation. Launched in 2022 for diagnostic and therapeutic purposes.
  • Alanylglutamine API (丙氨酰谷氨酰胺原料药) Active pharmaceutical ingredient for alanylglutamine injection, produced under GMP certification. The company manufactures both the API and finished dosage forms. Supplied to domestic and international pharmaceutical manufacturers.

Quantifiable outcome

  • Flurbiprofen Axetil Injection reduced imported drug price by ~70% upon market entry, saving over 1 billion RMB annually for national medical insurance
  • +2 more outcomes

Companies that use Grand Life Sciences

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Grand Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Grand Life Sciences partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • 辽宁远大诺康生物制药有限公司 (Liaoning Grand Nucam Biopharmaceutical Co., Ltd.)coreStrategic or Co-development Partner · 1 January 2021In January 2020, the company underwent merger and restructuring, joining China Grand Group's pharmaceutical health segment through integration with Liaoning Grand Nucam. This provided access to Grand Group's broader resources, sales networks, and R&D capabilities. The company became part of Grand Nucam's 'Greater Wuhan' pharmaceutical platform. In August 2021, the company name officially changed from 武汉大安制药有限公司 to 远大生命科学(武汉)有限公司.
  • 华润湖北医药有限公司 (China Resources Hubei Pharmaceutical Co., Ltd.)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Key strategic distribution partner for安抚® (Flurbiprofen Axetil Injection) in Hubei province. One of China's largest state-owned pharmaceutical distribution companies.
  • 上海乐明医药 (Shanghai Laming Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Strategic commercial partner for安抚® product marketing and distribution, present at national launch events and regional promotions.
  • 北京盛世康源医药 (Beijing Shengshi Kangyuan Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Strategic commercial partner for安抚® product in the Beijing region market.
  • 广东康美药业 (Guangdong Kangmei Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Key distribution partner for安抚® product in the Guangdong province market.
  • 云南泰康医药 (Yunnan Taikang Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Strategic partner in Yunnan province for pharmaceutical product distribution, actively supported regional marketing meetings.
  • 合肥亿帆 (Hefei Yifan)minorChannel Partner/ Reseller/ Distributor · 1 January 2018Regional commercial partner for安抚® product distribution in Anhui province, participated in national launch event.
  • 南京星鲨 (Nanjing Xingsha)minorChannel Partner/ Reseller/ Distributor · 1 January 2018Regional commercial partner for安抚® distribution in Jiangsu province.
  • 河南金保康 (Henan Jinbaokang)minorChannel Partner/ Reseller/ Distributor · 1 January 2018Regional commercial partner for安抚® distribution in Henan province.
  • 华中科技大学同济医学院 (HUST Tongji Medical College)coreStrategic or Co-development Partner · 1 January 2015The company is designated as a teaching base for HUST Tongji Medical College's School of Pharmacy, facilitating joint talent cultivation and academic exchange programs.
  • 武汉理工大学 (Wuhan University of Technology)minorStrategic or Co-development Partner · 1 January 2015Designated as a teaching base for collaborative education programs in pharmaceutical sciences and related fields.
  • 武汉轻工大学 (Wuhan Polytechnic University)minorStrategic or Co-development Partner · 1 January 2015Designated as a teaching base for collaborative education programs in pharmaceutical sciences.
  • 华中科技大学 (Huazhong University of Science and Technology)coreStrategic or Co-development Partner · 1 January 2008Long-standing strategic R&D partnership with Huazhong University of Technology (HUST). Professor Chen Bangyin (陈邦银), a State Council special allowance recipient, serves as a special expert. HUST faculty collaborate on research projects including the enterprise academician expert workstation. The company is a HUST Tongji School of Pharmacy teaching base.
  • 武汉大学 (Wuhan University)coreStrategic or Co-development Partner · 1 January 2008Strategic collaboration with Wuhan University. Professor Shu Jiayou (束家有), a State Council special allowance recipient, serves as a special expert and consultant. Dr. Huang Ling was appointed as a graduate student supervisor (校外兼职导师) by Wuhan University School of Pharmacy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Grand Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Mochida Pharmaceutical: Original Japanese developer of Flurbiprofen Axetil (Ropion®) whose technology monopoly Grand Life Sciences' Anfu® broke. Comparable as the originator of the same molecule and a broader specialty injectable manufacturer.
  • Livzon Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical company with injectable, API, and specialty drug products. Comparable in scale and GMP-certified manufacturing for Chinese hospital markets.
  • Jiangsu Hengrui Medicine: China's largest innovative pharmaceutical company with broad specialty injectable portfolio, including perioperative and oncology supportive care products. Comparable in targeting the same hospital channels and VBP procurement.
  • Yangzi River Pharmaceutical: Major domestic Chinese pharmaceutical company with a broad specialty injectable and analgesic portfolio. Competes in the same hospital channels and VBP procurement framework.
  • Sino Biopharmaceutical: Major Hong Kong-listed Chinese pharmaceutical company with a wide portfolio of injectable and specialty drugs. Competes in similar VBP channels and hospital formularies with comparable product breadth.

Direct peers

  • CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical major that produces Flurbiprofen Axetil Injection and other injectable analgesic products, directly competing with Anfu® in the same hospital and VBP channels. Comparable in scale and product category.
  • KPC Pharmaceuticals (Kunyao Group): Chinese pharmaceutical company with established injectable product portfolios including analgesics and specialty injectables. Both target hospital channels and participate in China's national VBP, making them a direct competitor in the domestic injectable space.
  • Hefei Life Sciences (Hefei Yi Fan / 合肥亿帆): Distribution partner of Grand Life Sciences for Anfu® in Anhui province. Listed as a regional pharmaceutical and distribution player that intersects with the company's commercial channel and product portfolio.

Emerging players

  • Nhwa Pharmaceutical (Jiangsu Nhwa): Chinese specialty pharmaceutical company focused on CNS and injectable products, with similar hospital-channel and VBP procurement participation. Comparable in operating scale and specialty injectable focus.

Others

  • China Resources Pharmaceutical (Huarun): State-owned pharmaceutical distribution and manufacturing conglomerate that operates China Resources Hubei Pharmaceutical, a key Grand Life Sciences distribution partner. Relevant as both a channel partner and ecosystem participant in China's pharmaceutical supply chain.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Grand Life Sciences compliance and trust

Trust signal

Compliance5 records

Grand Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Grand Life Sciences leadership team

Management profile

Number of profiles

Profiles15 records

Grand Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Grand Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grand Life Sciences

What does Grand Life Sciences do?

Grand Life Sciences is a high-tech pharmaceutical manufacturer that integrates drug R&D, production, and sales of injectable medications, active pharmaceutical ingredients, and oral preparations. Its core commercial products are Flurbiprofen Axetil Injection (Anfu®), a lipid microsphere-based targeted analgesic for post-operative and cancer pain, and Simethicone Emulsion (Anboshi®) for gastrointestinal applications. The company operates an 80,000 sqm GMP-certified manufacturing complex in Wuhan covering large-volume infusions, small-volume injections, freeze-drying, and API production, and distributes products to Chinese hospitals through national VBP procurement and provincial distribution partners.

Is Grand Life Sciences a public or private company?

Grand Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Grand Life Sciences founded?

Grand Life Sciences was founded in 2003.

Where is Grand Life Sciences based?

Grand Life Sciences is headquartered in Wuhan, China, in the Asia region.

How does Grand Life Sciences make money?

One revenue line is on record: pharmaceutical Product Manufacturing and Sales.

Who are Grand Life Sciences's main competitors?

Broad incumbents on record are Mochida Pharmaceutical, Livzon Pharmaceutical Group, Jiangsu Hengrui Medicine, Yangzi River Pharmaceutical and Sino Biopharmaceutical. Direct peers are CSPC Pharmaceutical Group, KPC Pharmaceuticals (Kunyao Group) and Hefei Life Sciences (Hefei Yi Fan / 合肥亿帆). Nhwa Pharmaceutical (Jiangsu Nhwa) is listed as an emerging player. China Resources Pharmaceutical (Huarun) is listed as an others.

Does Grand Life Sciences have an API?

No public API is recorded for Grand Life Sciences.

What industry is Grand Life Sciences in?

Grand Life Sciences's product category is Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HemophilianewstodayDeal aims to bring hemophilia A gene therapy BBM-H803 to ChinaGrand Life Sciences has entered into a collaboration agreement with Belief Biomed to commercialize BBM-H803, a gene therapy for hemophilia A in Greater China, contingent upon its approval. The therapy, currently in clinical trials, aims to provide a long-term treatment option to reduce bleeding episodes in patients.BioSpaceBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese PatientsBelief BioMed and Grand Life Sciences have announced an exclusive collaboration agreement granting Grand Life Sciences the rights to commercialize Belief BioMed's investigational gene therapy BBM-H803 for hemophilia A in Mainland China, Hong Kong, Macau, and Taiwan. The therapy, an AAV-based treatment with independent intellectual property rights, has received Orphan Drug Designation from the US FDA and IND approval from China NMPA. The partnership aims to leverage Belief BioMed's R&D expertise and Grand Life Sciences' commercialization platform to address the unmet clinical needs of over 30,000 registered hemophilia A patients in China who currently rely on factor VIII replacement therapy.PR NewswireBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese PatientsBelief BioMed and Grand Life Sciences announced on March 23, 2026 an exclusive collaboration agreement granting Grand Life Sciences the rights to commercialize Belief BioMed's investigational gene therapy BBM-H803 for Hemophilia A across Mainland China, Hong Kong China, Macau China, and Taiwan China. The partnership combines Belief BioMed's clinical development expertise with Grand Life Sciences' commercialization platform and nationwide sales network to accelerate patient access to the therapy. BBM-H803, an AAV-based gene therapy with orphan drug designation and rare pediatric disease designation from the U.S. FDA, is currently undergoing clinical trials and has received Investigational New Drug approval from China's NMPA.YahooBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese PatientsBelief BioMed and Grand Life Sciences Group Co., Ltd. announced an exclusive collaboration agreement granting Grand Life Sciences rights to commercialize Belief BioMed's investigational gene therapy BBM-H803 for Hemophilia A in Mainland China, Hong Kong China, Macau China, and Taiwan China. The partnership combines Belief BioMed's clinical development expertise with Grand Life Sciences' commercialization platform and market channels. Belief BioMed previously launched China's first gene therapy for Hemophilia B in 2025, and this agreement aims to accelerate patient access to innovative gene therapy treatments in the Chinese market.Thailand Business NewsBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese PatientsBelief BioMed and Grand Life Sciences announced an exclusive commercial partnership for the gene therapy product BBM-H803, an AAV-based treatment for hemophilia A, covering Mainland China, Hong Kong, Macau, and Taiwan. Under the agreement, Grand Life Sciences gains exclusive rights to commercialize BBM-H803, leveraging its blood product resources and hematology expertise to accelerate patient access to innovative gene therapy. The partnership addresses the unmet medical needs of over 30,000 registered hemophilia A patients in China, who currently rely primarily on factor VIII replacement therapy with associated infection risks and administration burdens.MorningstarBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese PatientsBelief BioMed (BBM) and Grand Life Sciences have entered into an exclusive collaboration agreement granting Grand Life Sciences commercial rights to BBM's investigational AAV-based gene therapy BBM-H803 for Hemophilia A in Mainland China, Hong Kong China, Macau China, and Taiwan China. The partnership combines Belief BioMed's clinical development expertise with Grand Life Sciences' commercialization platform and market channels, with the aim of accelerating patient access to the therapy. BBM-H803 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA, and its IND application was approved by China NMPA in July 2023.PR Newswire APACBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese PatientsBelief BioMed and Grand Life Sciences signed an exclusive commercial collaboration agreement granting Grand Life Sciences rights to commercialize Belief BioMed's investigational gene therapy BBM-H803 for Hemophilia A in Mainland China, Hong Kong China, Macau China, and Taiwan China. The partnership combines Belief BioMed's clinical development expertise with Grand Life Sciences' commercialization platform and market channels to accelerate patient access to the therapy. Belief BioMed had previously launched China's first gene therapy for Hemophilia B in 2025, and BBM-H803 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA, along with IND approval from China's NMPA.